S
Scholar Rock Holding Corporation (SRRK)
NMS – Real vaqt narxi. Valyuta: USD
49.19
+0.84 (1.74%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
49.19
+0.84 (1.74%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Scholar Rock Holding Corporation, biopharmaceutical kompaniyasi, spinal mushak atrofiyasi (SMA) va boshqa kam uchraydigan, og'ir va nogironlikka olib keladigan neyromuskulyar kasalliklarga chalingan bolalar va kattalar hayotini yaxshilashga qaratilgan. Kompaniyaning o'sayotgan omilning transformatsiya qiluvchi o'sayotgan omil beta (TGFβ) oilasidagi faollashuvining molekulyar mexanizmlarini yangicha tushunishi o'ziga xos platformani ishlab chiqishga imkon berdi. Ushbu platforma o'sayotgan omillarning prekursor yoki latent shakllarini mahalliy va tanlab nishonga oladigan monoklonal antitelalarni ishlab chiqish uchun ishlatiladi. Kompaniya apitegromabni ishlab chiqmoqda, bu miyostatinning faollashuvining ingibitori bo'lib, u SMA va fasiyskulopulo-humeral mushak distrofiyasi (FSHD) davolash uchun 2-bosqichli klinik sinovdan o'tmoqda. Bundan tashqari, SRK-439, anti-pro/latent miyostatin antikori, kam uchraydigan, og'ir va nogironlikka olib keladigan neyromuskulyar kasalliklarga chalingan bemorlarni davolash uchun 1-bosqichli klinik sinovda. SRK-181 - bu anti-PD-(L)1 antitelali terapiyalariga chidamli bo'lgan qattiq o'smalarga chalingan bemorlarni davolash uchun latent TGFβ1 ning tadqiq qilinayotgan ingibitori bo'lib, 2-bosqichga tayyor. Kompaniya, shuningdek, fibrotik kasalliklarni davolash uchun fibrotik tashqi matritsada selektiv faollikka ega bo'lgan latent TGFβ1 izoformasining selektiv ingibitori bo'lgan SRK-373 va temir bilan cheklangan anemiyalarni davolash uchun RGMc, yoki gemojuvelinning ingibitori bo'lgan SRK-256 ni o'z ichiga olgan preklinik rivojlanishdagi mahsulotlarni taklif etadi. Scholar Rock Holding Corporation, shuningdek, kam uchraydigan, og'ir va nogironlikka olib keladigan neyromuskulyar kasalliklarga chalingan bemorlarni davolash dasturlarini o'z ichiga olgan quvurlarni ishlab chiqmoqda. Scholar Rock Holding Corporation 2012-yilda tashkil etilgan va shtab-kvartirasi Massachusets shtatining Kembrij shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Akshay Krishnadas Vaishnaw M.D., Ph.D. | President of R&D, Member of Scientific Advisory Board and Director |
| Mr. David L. Hallal | CEO & Chairman of the Board |
| Mr. Mo Qatanani Ph.D. | Chief Scientific Officer |
| Mr. Robert Keith Woods | Chief Operating Officer |
| Mr. Vikas Sinha C.A., CPA, M.B.A. | CFO & Treasurer |
| Ms. Caryn Parlavecchio | Chief Human Resources Officer |
| Ms. Erin Moore CPA | Interim Principal Financial & Accounting Officer |
| Ms. Junlin Ho J.D. | General Counsel & Corporate Secretary |
| Ms. Lisa Wyman M.S. | Chief Technical & Quality Officer |
| Ms. Rushmie Nofsinger | Vice President of Corporate Affairs & Investor Relations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 10-Q | srrk-20260331x10q.htm |
| 2026-04-22 | DEF 14A | tm261440-1_def14a.htm |
| 2026-03-31 | 8-K | tm2610664d1_8k.htm |
| 2026-03-03 | 8-K/A | tm267900d1_8ka.htm |
| 2026-01-12 | 8-K | srrk-20260112x8k.htm |
| 2025-12-02 | 8-K | tm2532170d1_8k.htm |
| 2025-10-14 | 8-K | tm2528675d1_8k.htm |
| 2025-09-23 | 8-K | tm2526733d1_8k.htm |
| 2025-08-06 | 8-K | srrk-20250806x8k.htm |
| 2025-08-06 | 10-Q | srrk-20250630x10q.htm |